等级
pharmaceutical primary standard
API类
etomidate
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
SMILES字符串
CCOC(=O)c1cncn1[C@H](C)c2ccccc2
InChI
1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1
InChI key
NPUKDXXFDDZOKR-LLVKDONJSA-N
基因信息
human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Etomidate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
依托咪酯(Etomidate)是一种全身麻醉药；可激活GABAA信号通路。已有研究，依托咪酯对大鼠脑和脊髓中链脲菌素诱导(STZ-induced)的高血糖具有神经保护作用。依托咪酯治疗对神经组织具有抗糖尿病氧化损伤的神经保护作用。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Stewart G Albert et al.
Intensive care medicine, 37(6), 901-910 (2011-03-05)
Although etomidate is a preferred anesthetic agent for rapid sequence intubation (RSI) in critical illness, as an inhibitor of cortisol synthesis (11β-hydroxylase), it may be associated with adrenal dysfunction. The objectives are to review the effects of etomidate versus comparator
Antoine J Cherfan et al.
Pharmacotherapy, 32(5), 475-482 (2012-04-11)
Etomidate is a potent imidazole hypnotic used widely in single doses in the rapid sequence intubation of critically ill patients with sepsis due to its presumed hemodynamic safety, fast onset, and short duration of action. However, the literature is conflicting
Veronica A Preda et al.
European journal of endocrinology, 167(2), 137-143 (2012-05-12)
This review addresses the practical usage of intravenous etomidate as a medical therapy in Cushing's syndrome. We reviewed the relevant literature, using search terms 'etomidate', 'Cushing's syndrome', 'adrenocortical hyperfunction', 'drug therapy' and 'hypercortisolaemia' in a series of public databases. There
Stuart A Forman
Anesthesiology, 114(3), 695-707 (2011-01-26)
This review focuses on the unique clinical and molecular pharmacologic features of etomidate. Among general anesthesia induction drugs, etomidate is the only imidazole, and it has the most favorable therapeutic index for single-bolus administration. It also produces a unique toxicity
Chee Man Chan et al.
Critical care medicine, 40(11), 2945-2953 (2012-09-14)
To evaluate the effects of single-dose etomidate on the adrenal axis and mortality in patients with severe sepsis and septic shock. A systematic review of randomized controlled trials and observational studies with meta-analysis. Literature search of EMBASE, Medline, Cochrane Database
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门